Search company, investor...

Founded Year

2016

Stage

Series B | Alive

Total Raised

$51.33M

Last Raised

$41.2M | 2 yrs ago

About Epsilogen

Epsilogen focuses on the development of immunoglobulin E (IgE) antibodies. The company's main offerings include the development of IgE-based drugs that are designed to treat solid tumors, leveraging the potency, enhanced tumor access, and long tissue half-life of IgE. It primarily serves the oncology sector of the healthcare industry. Epsilogen was formerly known as IGEM Therapeutics. It was founded in 2016 and is based in London, United Kingdom.

Headquarters Location

Waterfront, ARC West London Manbre Road, Hammersmith

London, England, W6 9RH,

United Kingdom

+44(0)203 657 7612

Loading...

Loading...

Epsilogen Patents

Epsilogen has filed 3 patents.

The 3 most popular patent topics include:

  • antibodies
  • clusters of differentiation
  • immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/4/2011

10/10/2017

Monoclonal antibodies, Experimental cancer drugs, Oncology, Epidermal nevi, neoplasms, cysts, Monoclonal antibodies for tumors

Grant

Application Date

10/4/2011

Grant Date

10/10/2017

Title

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Oncology, Epidermal nevi, neoplasms, cysts, Monoclonal antibodies for tumors

Status

Grant

Latest Epsilogen News

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman

Nov 14, 2023

Highly experienced biotech veteran to support SENISCA’s rapid development of its senotherapeutic platform Exeter, UK — 14 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, today announces the appointment of Dr. David Chiswell Ph.D, OBE as Chairman of the Board. Dr. David Chiswell is one of the UK’s most successful biotechnology executives, with extensive experience in the development of early-stage biotechnology companies over 30 years in the industry. He joins the SENISCA Board having co-founded Cambridge Antibody Technology (CAT) in 1990 and served as its Chief Executive Officer (‘CEO’) from 1996 to 2002, taking CAT onto both the London Stock Exchange and Nasdaq. He also served as CEO of Nabriva Therapeutics from 2009 to 2012, following which he was appointed as CEO of Kymab Ltd. from 2015 to 2018. Dr. Chiswell currently serves as Chairman of Epsilogen Ltd. and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund (LSE:MNTN). Dr. Chiswell has served as the Chairman of the Board of various biotechnology companies including Albireo, Arrow and Sosei. He was also formerly Chairman of the UK BioIndustry Association, with his major contributions to the industry being recognized with the awarding of an OBE by HM the Queen in 2006. Dr. Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chiswell to our Board at SENISCA. His deep knowledge and expertise in the biotechnology sector – particularly in early-stage companies, combined with his strategic expertise will be crucial as we continue our evolution towards becoming a clinical stage biotechnology company developing novel senotherapeutics to treat age-related disease. Our ability to attract someone of David’s calibre speaks volumes about the quality of our science and the strong foundational work our team has undertaken.” Dr. David Chiswell, Chairman of the Board of SENISCA commented: “SENISCA is a revolutionary company with the potential to transform the landscape of senotherapeutic treatments. I am thrilled to be joining the Company as Chairman, and I look forward to collaborating with the Board and leadership team as SENISCA progresses into the next stage of its development.” - Ends - About SENISCA SENISCA is an award-winning, RNA therapeutics spinout from the University of Exeter. The Company is focused on modulating RNA biology to treat age-related disease. Underpinned by more than 15 years of world-leading research, SENISCA has identified an officially recognized, novel and druggable component of the cellular ageing (senescence) response, which can be specifically targeted in the context of multiple pharmacological and skin health indications. The Company is developing a portfolio of proprietary senotherapeutics, that target cell senescence for cellular rejuvenation in the treatment of age-related disease. SENISCA’s senotherapeutics specifically target the novel cellular pathway which causes cell rejuvenation and positively impacts markers of disease modification in patient-derived models. In line with the rapid evolution of the company, R & D activities are focused on IND data generation. SENISCA’s platform technology has broad applicability for multiple age-related diseases including those of the eyes, lungs, joints, and brain. For many such diseases, current treatments are palliative rather than curative, with varying success rates. These diseases represent a high unmet medical need, are amenable to a local route of therapeutic administration and are driven by senescence. Targeting these specific diseases will streamline progress towards the clinic by avoiding potential pitfalls of systemic delivery. SENISCA’s novel senotherapeutics will be mined and commercialized through partnership or co-development models that will sit alongside internal programmes. If you would like to learn more about SENISCA, please contact Jennie Jepperson, Executive Assistant at SENISCA ( Jennie.Jepperson@senisca.com ).

Epsilogen Frequently Asked Questions (FAQ)

  • When was Epsilogen founded?

    Epsilogen was founded in 2016.

  • Where is Epsilogen's headquarters?

    Epsilogen's headquarters is located at Waterfront, ARC West London, London.

  • What is Epsilogen's latest funding round?

    Epsilogen's latest funding round is Series B.

  • How much did Epsilogen raise?

    Epsilogen raised a total of $51.33M.

  • Who are the investors of Epsilogen?

    Investors of Epsilogen include ALSA Ventures, Epidarex Capital, Schroders, 3B Future Health Fund, Novartis Venture Funds and 6 more.

  • Who are Epsilogen's competitors?

    Competitors of Epsilogen include Harpoon Therapeutics, Pionyr Immunotherapeutics, OncoResponse, Immune-Onc Therapeutics, Fortis Therapeutics and 7 more.

Loading...

Compare Epsilogen to Competitors

OncoResponse Logo
OncoResponse

OncoResponse develops therapeutic antibodies for the treatment of cancer by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (CPI). It develops cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. The company was founded in 2015 and is based in Seattle, Washington.

I
ImmunoMet Therapeutics

ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies. The company develops a molecule that targets the oxidative phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and selects cancer cells. It was founded in 2015 and is based in Houston, Texas.

Immune-Onc Therapeutics Logo
Immune-Onc Therapeutics

Immune-Onc Therapeutics is a clinical-stage company that focuses on the development of novel myeloid checkpoint inhibitors in the healthcare and biotechnology industry. The company's main offerings include the development of immunotherapies for cancer, harnessing the body's own immune system to fight against disease, with a particular focus on blood cancers and solid tumors. Immune-Onc primarily sells to the healthcare industry, specifically in the field of cancer treatment. It was founded in 2016 and is based in Palo Alto, California.

F
Fortis Therapeutics

Fortis Therapeutics is a company focused on the development of novel, first-in-class therapeutics in the healthcare and biotechnology industry. The company's main offerings include precision therapies that target CD46 proteins in cancer cells, while sparing normal tissues. The company primarily serves the healthcare industry, specifically the oncology sector. It was founded in 2016 and is based in La Jolla, California.

Macrophage Pharma Logo
Macrophage Pharma

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.

OncoOne Logo
OncoOne

OncoOne focuses on the development of therapeutic antibodies in the biotechnology sector, specifically targeting a novel innate immunity target known as oxidized Macrophage Migration Inhibitory Factor (oxMIF) for cancer and chronic inflammation. The company's main offerings include anti-oxMIF antibodies designed to enhance patient outcomes in cancer and inflammation, with products such as ON203 for solid tumors and ON104 for chronic inflammatory and autoimmune disorders. These antibodies can be used both as monotherapies and in combination with existing treatments. It was founded in 2018 and is based in Klosterneuburg, Austria.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.